Targeting the HGF/Met signaling pathway in cancer therapy - Wikidata - wikimedia - TriplyDB

Targeting the HGF/Met signaling pathway in cancer therapy

Targeting the HGF/Met signaling pathway in cancer therapy

http://www.wikidata.org/entity/Q37013777

about

Pharmacogenetics and pharmacogenomics as tools in cancer therapy EGFR-TKI resistance in NSCLC patients: mechanisms and strategies Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration.Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer Renal cell carcinoma: molecular biology and targeted therapy Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy Artificial human Met agonists based on macrocycle scaffolds Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways.Targeted therapy in gastroesophageal cancers: past, present and future.Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors.Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6.MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction.Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features.miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression.Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function.Hepatocyte growth factor and basic fibroblast growth factor regulate atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease via the mitogen-activated protein kinase signaling pathway Differential Roles of Carboxylated and Uncarboxylated Osteocalcin in Prostate Cancer Growth.Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma.Stromal Androgen Receptor in Prostate Cancer Development and Progression MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.Different growth and metastatic phenotypes associated with a cell-intrinsic change of Met in metastatic melanoma.Effects of hepatocyte growth factor on MMP-2 expression in scleral fibroblasts from a guinea pig myopia model.Hepatocyte growth factor/MET in cancer progression and biomarker discovery Mechanisms of RAS/β-catenin interactions.Current role of cabozantinib in metastatic castration-resistant prostate cancer.The role of genomics in the management of advanced bladder cancer.Hepatocyte growth factor and Met in drug discovery.Gene of the month: MET.

P2860

Q28076200-CAF43895-3F59-4802-904B-D503005806B8 Q28394310-CEDEBF0D-AFB0-4244-B750-BFCEFB57F8D6 Q30368024-B09A2E48-290D-43D6-82AB-7F94D1237A45 Q33414632-F242D63E-3074-4EED-9E71-57511A812C87 Q33682988-BC3C752A-1A33-4153-99C5-259EFB96568E Q33756991-7D0BE6E1-823C-46E7-A878-9B7CE762D1D7 Q33762943-E5CE017D-01F1-4996-BC83-AAF05518D009 Q33830522-F52C7C43-F552-449D-870C-33F22674EEA9 Q33917507-6E3FAE06-A57C-44C3-BF62-A46AECB76F2B Q34104074-495D5E50-5115-40A8-9F1F-9E7DD6BC52B9 Q34513914-7AF72603-0C76-4202-AD55-095E9ADD2A5D Q34774912-104767EB-18CC-4F8C-A475-7B74D071C3DF Q34812142-C3F241CD-D6EA-41AF-8E8F-D047B90BDD12 Q34984377-3E571F62-3120-4537-B734-460200809E68 Q35036012-5EED7A34-8903-4221-A8C5-88E291347E6F Q35129076-651691C5-9CF5-4348-B791-D06BE23323E5 Q35245109-98455786-F152-4B6A-B4AB-4399E01953AB Q36051783-4BDAA147-14E7-4347-9D86-A7FFA04ED4DA Q36180749-CB7CFDC5-1A2F-47B5-9B94-E8935068CEC2 Q36294579-5996478E-357E-42A6-9005-EEA4C53ED389 Q36383040-4296B115-42E3-4843-B66E-225CDCD8FCEE Q36487012-5D1CD194-9D0C-4C06-BC72-E149F62E419A Q36520263-579596F6-DC39-4F66-BB63-297AA36A17D4 Q36766188-DDC9969F-07B9-4A55-B725-11A8AA9A6EB8 Q36956224-CE3127E8-ACE5-4244-BEC3-C664F98A121A Q36983766-F5F9E4BF-ECA9-479B-A037-1855211EA1D3 Q37054475-61EED728-ECED-4110-9553-4E6D53739E44 Q37289110-CAA3F996-30B3-4B9F-8BDF-B1F2CDFF3812 Q37290529-8EDCABE3-3BBD-499C-8E63-C007C3452427 Q37544362-4B3B3945-717F-4BDA-9CDD-90C39998D110 Q37629551-B8D3280F-BD0F-448A-810E-959D28B31896 Q37682961-434ECFFA-F400-44CA-AA9B-D007AF533A58 Q37688612-5B8B1597-51CB-4AD2-8A18-240A832AA972 Q37729412-1CB30629-8997-41CE-A06A-EB090DD43C48 Q37735624-98E286D0-C073-4104-9A26-D62A079C3EA4 Q38088654-E1D996DA-559E-4668-A105-23E66D956DDC Q38317384-CB12D2DD-7054-4894-8BB9-CBEF6C85EC5C Q38342992-AB2B118D-1223-4ABC-95AA-1F0A821E42DA Q38377273-B9BFC248-BE16-4E09-A4D8-4229AB7F878A Q38490458-F8FA5022-AB33-4660-8C12-C08A7623C315

P2860

Targeting the HGF/Met signaling pathway in cancer therapy

http://www.wikidata.org/entity/Q37013777

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 April 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting the HGF/Met signaling pathway in cancer therapy

@en

Targeting the HGF/Met signaling pathway in cancer therapy.

@nl

type

label

Targeting the HGF/Met signaling pathway in cancer therapy

@en

Targeting the HGF/Met signaling pathway in cancer therapy.

@nl

prefLabel

Targeting the HGF/Met signaling pathway in cancer therapy

@en

Targeting the HGF/Met signaling pathway in cancer therapy.

@nl

P1433

Q37013777-F8184F36-FC6E-404A-8F6F-D58E6F1728EF

P1476

Q37013777-54C46DB5-B833-4FE6-8F38-7538339BD28F

P2093

Q37013777-681F248C-4EE9-4723-83A1-4E5471D3EA46

Q37013777-8E91B669-7FED-4D27-8565-15ACB08F48FF

P2860

Q37013777-0132FF2C-EF44-403C-B45A-7ACE51A78324

Q37013777-01C61164-F670-4403-80FD-30B6C8E6C83A

Q37013777-024B729B-656E-481C-999F-C2E6C63F4A91

Q37013777-027BD37E-9873-4B01-919B-F250B23771BE

Q37013777-03E13F95-20AC-4434-8632-E909D5123AD6

Q37013777-09DE1F86-A6FE-49B6-824E-631B29A59DED

Q37013777-0BF6258D-2C97-46EC-8E51-4954C7C50CFC

Q37013777-114E48FC-8BE0-40A6-8783-21EE68028D02

Q37013777-1866429E-F847-406D-805C-D21EFC6F74AD

Q37013777-1B34825C-9449-45C8-A819-5AE5F372DEBB

P304

Q37013777-F41D56B3-F541-4877-BA9E-45A8A11B62EB

P31

Q37013777-BEB4E756-EB76-40F3-8860-D5F5F6D7A16C

P356

Q37013777-CACC4058-BCCA-401D-8ABB-B7B81E00027F

P407

Q37013777-199DDC4E-1A88-43F4-BD01-1AD5A37E12E2

P433

Q37013777-DAD6A188-D85E-4BBD-A8F9-FB6C72A95FA9

P478

Q37013777-4A9BFC23-EEE8-4B19-A844-E60BFEAE3AE3

P50

Q37013777-70E69919-749F-4B5B-B133-8ECB4E3AFEEB

P577

Q37013777-DBC6CEEC-C581-4E32-AC4B-379BD6A44C8A

P5875

Q37013777-575F8737-B3E5-4479-9FDA-8EDBA9CBF5E6

P698

Q37013777-F8BC3E7C-ED32-429F-AE71-AD7587B6E356

P932

Q37013777-06FF4E8F-DF18-48AA-8E14-A8794E72404B

P356

14728222.2012.680957

P1433

Expert Opinion on Therapeutic Targets

P1476

Targeting the HGF/Met signaling pathway in cancer therapy

@en

P2093

Danie C Rabe

http://www.w3.org/2001/XMLSchema#string

Fabiola Cecchi

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor

Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197

Structure of the semaphorin-3A receptor binding module

The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily

P304

553-572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2012.680957

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Donald P. Bottaro

P577

2012-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224834735

http://www.w3.org/2001/XMLSchema#string

P698

22530990

http://www.w3.org/2001/XMLSchema#string

P932

3711667

http://www.w3.org/2001/XMLSchema#string